BEVERLY, Mass., Sept. 26 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST(TM) -- Progesterone VGS 25. It is the newest addition to its Progesterone Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line, which already includes FIRST(TM) -- Progesterone VGS 50, 100, and 200. The kits are made for one patient and include pre-measured, pre-weighed bioidentical progesterone and a unique, patent pending disposable suppository mold for preparation, dispensing, and storage of the suppositories, all in one unit that increases patient ease of use.
FIRST(TM) products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST(TM) VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared in the conventional way using a metal suppository mold or polystyrene shells. A single NDC number assigned for the entire Kit offers easy third party reimbursement and reduces audit-related adjustments.
“Now that our simple unit-of-use kits are available at local neighborhood pharmacies, it will make it very convenient for patients to fill such custom prescriptions,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “With the launch of 25 mg strength and the planned launch of 400 mg in the fourth quarter of 2006, physicians will have a wide range of FIRST(TM) compounded progesterone suppositories to offer their patients.”
CutisPharma currently has eight proprietary prescription compounding kits on the market: four progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. Several more compounding kits are in the planning stages. FIRST(TM) Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.
The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
About CutisPharma
CutisPharma, Inc. based in Beverly, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(TM) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. A U.S. patent has been issued to the Company and additional patents are pending.
Contact: James Nagle V.P. Business Development CutisPharma, Inc. 978-867-1010 x20 jnagle@cutispharma.com
For more information please visit our website at http://www.cutispharma.com
CutisPharma, Inc.
CONTACT: James Nagle, V.P. Business Development of CutisPharma, Inc.,+1-978-867-1010, ext. 20, jnagle@cutispharma.com
Web site: http://www.cutispharma.com/
